Thonzonium bromide

CAS: 553-08-2 F: C32H55BrN4O W: 591.71

Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM)[1][2][3].
Invitro	Thonzonium bromide inhibits RANKL-induced OC formation, the appearance of OC-specific marker genes and bone-resorbing activity in vitro. Thonzonium bromide blocks the RANKL-induced activation of NF-κB, ERK and c-Fos as well as the induction of NFATc1 which is essential for OC formation. Thonzonium bromide disrupts F-actin ring formation resulting in disturbances in cytoskeletal structure in mature OCs during bone resorption. Thonzonium bromide exhibits protective effects in an in vivo murine model of LPS-induced calvarial osteolysis[1].
Name	Thonzonium bromide
CAS	553-08-2
Formula	C32H55BrN4O
Molar Mass	591.71
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Reference	[1]. Zhu X, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:118-130. [2]. Chan CY, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem. 2012;287(13):10236-10250. [3]. Sims KR, et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery. Nanoscale. 2018;11(1):219-236.